<span item_type="fundamental" item_id="05dcd7f050199f470d6d905cd38b8d06" counter_id="ST/US/CI" env="prod"></span><span item_type="announcement" item_id="544220061639707009" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 67.18 B, beating the estimate of USD 62.61 B.</p><p>EPS: As of FY2025 Q2, the actual value is USD 5.71, missing the estimate of USD 5.8315.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenues</strong>: The Cigna Group reported total revenues of $67.2 billion for the second quarter of 2025, an increase of 11% compared to the second quarter of 2024, primarily driven by growth in Evernorth Health Services and strong specialty pharmacy growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Shareholders’ Net Income</strong>: For the second quarter of 2025, shareholders’ net income was $1.5 billion, or $5.71 per share, compared to $1.5 billion, or $5.45 per share, for the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li><li><strong>Adjusted Income from Operations</strong>: Adjusted income from operations for the second quarter of 2025 was $1.9 billion, or $7.20 per share, reflecting a 1% increase from the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li><li><strong>SG&amp;A Expense Ratio</strong>: The SG&amp;A expense ratio was 5.1% for the second quarter of 2025, compared to 6.1% in the second quarter of 2024, indicating a shift in business mix and strong revenue growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Investment Results</strong>: Net investment results from equity method investments were - $44 million for the second quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Evernorth Health Services</strong>: Adjusted revenues for Evernorth Health Services increased by 17% and adjusted income from operations, pre-tax, increased by 5% compared to the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li><li><strong>Cigna Healthcare</strong>: Adjusted revenues decreased by 18% due to the impact of the HCSC transaction, but would have increased by 7% excluding this impact, driven by premium rate increases.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The Cigna Group reaffirms its 2025 outlook for adjusted income from operations of at least $29.60 per share, including the impact of expected future share repurchases and anticipated dividends. The outlook also includes Evernorth adjusted income from operations, pre-tax, of at least $7,200 million and Cigna Healthcare adjusted income from operations, pre-tax, of at least $4,125 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm"></span></li></ul>

Cigna | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 67.18 B